The next breakthrough in cancer treatment?
In our body, we have an innate immune system and an immune system that is…
January 31, 2023 - 4 minutes
Cancer: Keep up to Date with the Latest in Oncology
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
Show More
Editor's Picks for Cancer
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Immuno-Oncology: From Science Fiction to the Mainstream
- ADC Approval Buoys Spirits in Cancer Treatment Space
- Do Natural Killer Cells Hold the Key to Treating Blood Cancers?
- Meet 20 European Immuno-Oncology Companies that are Fighting Cancer
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest Cancer Articles
Stemline Therapeutics’ breast cancer treatment approved
The Menarini Group, an Italian pharmaceutical and diagnostics company, says that the U.S. Food and…
January 31, 2023 - 3 minutes
Singapore researchers use old drug as new acute leukemia treatment
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the…
January 31, 2023 - 4 minutes
Abbisko Therapeutics receives breakthrough therapy designation for CSF-1R inhibitor
Abbisko Therapeutics Co., Ltd. has announced that its CSF-1R inhibitor Pimicotinib has been granted the…
January 31, 2023 - 4 minutes
BiVictriX announces positive data from leukemia study
BiVictriX Therapeutics plc has announced positive in vivo data from a toxicity evaluation study with…
January 31, 2023 - 3 minutes
Beyond Biotech podcast 31: Orgenesis, Phacilitate, Terumo, University of Birmingham, VIVEBiotech
Phacilitate’s Advanced Therapies Week took place last week in Miami Beach, Florida. This week, we…
January 27, 2023 - 2 minutes
HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance
A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed)…
January 27, 2023 - 2 minutes
Onxeo to study prostate cancer drug
French biotech company Onxeo S.A. has given an update on the clinical development program of…
January 27, 2023 - 4 minutes
Scopio on the future of telehematology
Through full-field digital cell morphology, Scopio Labs’ technology can automate the analysis of tens of…
January 26, 2023 - 4 minutes
Lupus treatment hope from Japanese miRNA research
A group of researchers from the Graduate School of Medicine at Nagoya University in Japan…
January 26, 2023 - 5 minutes
Watch: pHion Therapeutics talks about next-generation mRNA vaccines
pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic…
January 23, 2023 - 1 minute
New drug could replace current standard for treating brain cancer
Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation…
January 20, 2023 - 3 minutes
